Title : Sitravatinib potentiates immune checkpoint blockade in refractory cancer models.

Pub. Date : 2018 Nov 2

PMID : 30385724






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Sitravatinib is a spectrum-selective tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MerTK) and split tyrosine-kinase domain-containing receptors (VEGFR and PDGFR families and KIT) plus RET and MET, targets that contribute to the immunosuppressive tumor microenvironment. sitravatinib kinase insert domain receptor Homo sapiens